Sign In
Buy TRDA
$6.58
-0.0600 (-0.90%)
At Close: Jun 03, 2026
Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why
09:51am, Wednesday, 11'th Dec 2024
Entrada Therapeutics (TRDA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it
Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why
09:52am, Monday, 25'th Nov 2024
Entrada Therapeutics (TRDA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed t
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates
09:16am, Tuesday, 05'th Nov 2024
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to earnings of $1.02 per share a year ago.
Here's Why Momentum in Entrada Therapeutics (TRDA) Should Keep going
09:50am, Thursday, 31'st Oct 2024
Entrada Therapeutics (TRDA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
07:00am, Wednesday, 09'th Oct 2024
– Additional positive data from the Company's completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports the planned Q4 2024 global regulatory filings for a P
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
07:00am, Tuesday, 24'th Sep 2024
BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellul
āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors
08:30am, Tuesday, 17'th Sep 2024
BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today annou
- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration of
Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates
09:20am, Tuesday, 13'th Aug 2024
Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to loss of $0.78 per share a year ago.
Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High?
10:56am, Thursday, 25'th Jul 2024
The mean of analysts' price targets for Entrada Therapeutics (TRDA) points to a 25.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a
Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last?
10:36am, Friday, 12'th Jul 2024
Entrada Therapeutics (TRDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near
Best Momentum Stocks to Buy for July 9th
11:16am, Tuesday, 09'th Jul 2024
CVNA, AL and TRDA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 9, 2024.
New Strong Buy Stocks for July 9th
08:35am, Tuesday, 09'th Jul 2024
CVNA, TRDA, BMBL, APEI and AL have been added to the Zacks Rank #1 (Strong Buy) List on July 9, 2024.
Entrada Therapeutics Announces $100 Million Registered Direct Offering
07:15am, Monday, 24'th Jun 2024
– The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – – The offering was led by a U.S.-based
– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, phy
